EVASION OF ANTIGEN PRESENTATION BY RHESUS CYTOMEGALOVIRUS

恒河猴巨细胞病毒逃避抗原呈递

基本信息

  • 批准号:
    7715925
  • 负责人:
  • 金额:
    $ 5.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-05-01 至 2009-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The major goal of this proposal is to identify and characterize cytomegaloviral immunomodulatory functions in vitro and to define their role for immune evasion in vivo. The recent completion of the RhCMV genomic sequence revealed a conservation of many immunomodulators identified in HCMV. Among those are viral genes preventing antigen presentation to T cells by major histocompatibility complex class I (MHC I) molecules. Work in several laboratories, including ours, previously uncovered that four glycoproteins of the US6-family (US2, US3, US6 and US11) inhibit assembly and transport of MHC I in HCMV-infected cells. We demonstrated that RhCMV encodes functional homologues for each of these four immunomodulators, (Rh182, Rh184, Rh185 and Rh189). In the course of these studies we made the unexpected and exciting discovery that RhCMV encodes an additional mechanism which intercepts biosynthesis of MHC I heavy chains (HC), but not light chains (beta2m), at a step that precedes the interference by US6-family proteins. This novel mechanism, termed viral interference with HC expression (VIHCE), has so far not been observed in HCMV-infected cells. The goals of this application are a) to examine whether MHC I interference mechanisms are important for evading CD8+ T cell control in vivo, b) to examine the importance of US6-related and -unrelated genes in immune evasion in vivo and c) to characterize the molecular mechanism of VIHCE. Specific Aim 1: Identification of the gene encoding VIHCE. The goal of this specific aim is to identify which open reading frame in the RhCMV-genome encodes the gene responsible for the VIHCE phenotype. Specific Aim 2: Functional characterization of VIHCE. The goal of this specific aim is to further characterize the VIHCE mechanism in cells infected with wildtype or VIHCE-deleted RhCMV. Specific Aim 3: The role of MHC I modulators for establishment and maintenance of persistent infection by RhCMV. We will examine the role of VIHCE and US6-related genes for viral immune evasion in a re-infection model in rhesus macaques.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Klaus J Fruh其他文献

Klaus J Fruh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Klaus J Fruh', 18)}}的其他基金

Non-canonical epitope presentation and antigen processing by MHC-E
MHC-E 的非典型表位呈递和抗原加工
  • 批准号:
    10801509
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
一种针对疟疾红细胞前阶段的巨细胞病毒疫苗
  • 批准号:
    9982274
  • 财政年份:
    2017
  • 资助金额:
    $ 5.55万
  • 项目类别:
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
一种针对疟疾红细胞前阶段的巨细胞病毒疫苗
  • 批准号:
    9238234
  • 财政年份:
    2017
  • 资助金额:
    $ 5.55万
  • 项目类别:
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
一种针对疟疾红细胞前阶段的巨细胞病毒疫苗
  • 批准号:
    9751633
  • 财政年份:
    2017
  • 资助金额:
    $ 5.55万
  • 项目类别:
An Effector Memory T Cell-Inducing Subunit Vaccine against Malaria
一种针对疟疾的效应记忆 T 细胞诱导亚单位疫苗
  • 批准号:
    8423271
  • 财政年份:
    2013
  • 资助金额:
    $ 5.55万
  • 项目类别:
An Effector Memory T Cell-Inducing Subunit Vaccine against Malaria
一种针对疟疾的效应记忆 T 细胞诱导亚单位疫苗
  • 批准号:
    8607501
  • 财政年份:
    2013
  • 资助金额:
    $ 5.55万
  • 项目类别:
MECHANISMS OF IMMUNE VULNERABILITY OF THE ELDERLY TO THE WEST NILE VIRUS
老年人对西尼罗河病毒免疫脆弱的机制
  • 批准号:
    8357751
  • 财政年份:
    2011
  • 资助金额:
    $ 5.55万
  • 项目类别:
EVASION OF ANTIGEN PRESENTATION BY RHESUS CYTOMEGALOVIRUS
恒河猴巨细胞病毒逃避抗原呈递
  • 批准号:
    8357750
  • 财政年份:
    2011
  • 资助金额:
    $ 5.55万
  • 项目类别:
MODULATION OF INNATE IMMUNE RESPONSES BY CYTOMEGALOVIRUS
巨细胞病毒对先天免疫反应的调节
  • 批准号:
    8357775
  • 财政年份:
    2011
  • 资助金额:
    $ 5.55万
  • 项目类别:
Development and Analysis of Replication-Deficient CMV Vectors
复制缺陷型 CMV 载体的开发和分析
  • 批准号:
    8117930
  • 财政年份:
    2011
  • 资助金额:
    $ 5.55万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 5.55万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 5.55万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 5.55万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 5.55万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 5.55万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 5.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了